Most research efforts in drug discovery and the repurposing of existing drugs for use in patients with atherosclerosis has so far largely focused on targeting systemic inflammation. Using single-cell analyses, Giannarelli Lab investigators have shown specific tissue specialization of innate and adaptive immune cells in human plaque versus blood in the same patient. Identifying new precise treatments that restore the function of immune cellular and molecular networks specifically acting in blood and/or in atherosclerotic lesions in the same patient is an innovative strategy to reduce both systemic and plaque inflammation and ultimately treat cardiovascular disease.